{"id":224,"date":"2010-03-31T14:24:12","date_gmt":"2010-03-31T05:24:12","guid":{"rendered":"http:\/\/www.med.miyazaki-u.ac.jp\/home\/menekikansen\/2010\/03\/31\/2005\/"},"modified":"2017-09-06T11:49:21","modified_gmt":"2017-09-06T02:49:21","slug":"2005","status":"publish","type":"post","link":"http:\/\/www.med.miyazaki-u.ac.jp\/home\/menekikansen\/achievement\/20100331224\/","title":{"rendered":"2005\u5e74\uff08\u5e73\u621017\u5e74\u5ea6\uff09\u306e\u7814\u7a76\u696d\u7e3e"},"content":{"rendered":"

A. \u8ad6\u6587<\/h3>\n

\u3010\u8457\u66f8\u3011<\/h4>\n
    \n
  1. \u5ca1\u5c71\u662d\u5f66. \u611f\u67d3\u75c7\u304a\u3088\u3073\u5bc4\u751f\u866b\u75be\u60a3. \u533b\u7642\u7981\u5fcc\u8a3a\u7642\u79d1\u5225\u30de\u30cb\u30e5\u30a2\u30eb, \u5bcc\u91ce\u5eb7\u65e5\u5df1, 224-241(2006).\u3000\u533b\u6b6f\u85ac\u51fa\u7248\u682a\u5f0f\u4f1a\u793e, \u6771\u4eac. (3\u6708)<\/li>\n<\/ol>\n

    \u3010\u539f\u8457\u3011<\/h4>\n
      \n
    1. Tanaka G, Okayama A, Watanabe T, Aizawa S, Stuver SO, Mueller NE, Hsieh CC, Tsubouchi H. The Clonal Expansion of Human T Lymphotropic Virus Type 1-Infected T Cells: A Comparison between Seroconverters and Long-Term Carriers. J Infect Dis. 2005;191:1140-1147. (April)<\/li>\n
    2. Doi K, Wu X, Taniguchi Y, Yasunaga J, Satou Y, Okayama A, Nosaka K, Matsuoka M. Preferential selection of human T-cell leukemia virus type I provirus integration sites in leukemic versus carrier states. Blood. 2005;106:1048-1053. (August)<\/li>\n
    3. \u9577\u53cb\u5b89\u5f18, \u77f3\u7530\u9686\u96c4, \u7530\u539f\u826f\u535a, \u843d\u5408\u4fca\u96c4, \u897f\u7530\u5353\u723e, \u7530\u4ee3\u5b8f\u4e00, \u7af9\u4e2d\u6643\u53f8, \u5927\u5712\u535a\u6587. \u80ba\u708e\u306b\u304a\u3051\u308b\u80ba\u708e\u7403\u83cc\u5c3f\u4e2d\u6297\u539f\u8fc5\u901f\u691c\u51fa\u30ad\u30c3\u30c8\u306e\u610f\u7fa9\u3068\u6709\u7528\u6027. \u5bae\u5d0e\u770c\u533b\u5e2b\u4f1a\u533b\u5b66\u4f1a\u8a8c.\u30002005;29:2,94-98. (9\u6708)<\/li>\n
    4. Watanabe M, Ohsugi T, Shoda M, Ishida T, Aizawa S, Maruyama-Nagai M, Utsunomiya A, Koga S, Yamada Y, Kamihira S, Okayama A, Kikuchi H, Uozumi K, Yamaguchi K, Higashihara M, Umezawa K, Watanabe T, Horie R. Dual targeting of transformed and untransformed HTLV-1-infected T cells by DHMEQ, a potent and selective inhibitor of NF-kappaB, as a strategy for chemoprevention and therapy of adult T-cell leukemia. Blood. 2005;106:2462-2471. (October)<\/li>\n
    5. Taniguchi Y, Nosaka K, Yasunaga J, Maeda M, Mueller N, Okayama A and Matsuoka M. Silencing of human T-cell leukemia virus type I gene transcription by epigenetic mechanisms. Retrovirology. 2005;2:64. (October).<\/li>\n
    6. Dewan MZ, Uchihara J, Terashima K, Honda M, Sata T, Ito M, Fujii N, Uozumi K, Tsukasaki K, Tomonaga M, Kubuki Y, Okayama A, Toi M, Mori N, Yamamoto N. Efficient intervention of growth and infiltration of primary adult T-cell leukemia cells by an HIV protease inhibitor, ritonavir. Blood. 2006;107:716-724. (January)<\/li>\n
    7. Aratake Y, Nomura H, Kotani T, Marutsuka K, Kobayashi K, Kuma K, Miyauchi A, Okayama A, Tamura K. Coexistent anaplastic and differentiated thyroid carcinoma, an immunohistochemical study. Am J Clin Pathol. 2006;125:399-406. (March)<\/li>\n<\/ol>\n

      \u3010\u75c7\u4f8b\u5831\u544a\uff08\u8ad6\u6587\uff09\u3011<\/h4>\n
        \n
      1. \u5bae\u5185\u4fca\u4e00, \u82a6\u8c37\u6df3\u4e00, \u4eca\u6d25\u5584\u53f2, \u4f50\u91ce\u3042\u308a\u3055, \u5e8a\u5cf6\u771e\u7d00, \u4e2d\u91cc\u96c5\u5149. \u51ac\u5b63\u306b\u767a\u75c7\u3057\u305f\u590f\u578b\u904e\u654f\u6027\u80ba\u708e\u306e\uff11\u4f8b. \u5bae\u5d0e\u770c\u533b\u5e2b\u4f1a\u533b\u5b66\u4f1a\u8a8c. \u30002005;29:1,61-63. (4\u6708)<\/li>\n
      2. \u6885\u5317\u90a6\u5f66, \u9ad8\u57ce\u4e00\u90ce, \u68ee\u7950\u4e00\u6717, \u4f50\u3005\u6728\u9686, \u6751\u4e95\u5e78\u4e00, \u5ca1\u5c71\u662d\u5f66, \u576a\u5185\u535a\u4ec1, \u4f0a\u85e4\u6d69\u53f2, \u7247\u5ca1\u5bdb\u7ae0. \u30b7\u30af\u30ed\u30db\u30b9\u30d5\u30a1\u30df\u30c9\u306b\u3088\u308a\u96e3\u6cbb\u6027\u4e0b\u817f\u6f70\u760d\u304c\u6539\u5584\u3057\u305f\u76ae\u819a\u578b\u7d50\u7bc0\u6027\u52d5\u8108\u708e\u306e\uff11\u4f8b. \u30ea\u30a6\u30de\u30c1\u79d1. 2005;33:570-574. (5\u6708)<\/li>\n
      3. \u4f50\u85e4\u4fe1\u4e5f, \u8352\u6b66\u516b\u8d77, \u76db\u53e3\u6e05\u9999, \u5927\u91ce\u62db\u4f38, \u65e5\u91ce\u6d66\u96c4\u4e4b, \u5ca1\u5c71\u662d\u5f66, \u6d45\u7530\u7950\u58eb\u90ce, \u4e38\u585a\u6d69\u52a9. \u637a\u5370\u7d30\u80de\u8a3a\u30ae\u30e0\u30b6\u67d3\u8272\u306b\u304a\u3044\u3066\u591a\u6570\u306e\u7d30\u80de\u5185\u9846\u7c92\u3092\u8a8d\u3081\u3001\u795e\u7d4c\u5185\u5206\u6ccc\u5206\u5316\u3092\u793a\u3057\u305f\u7537\u6027\u4e73\u764c\u306e\uff11\u4f8b. \u65e5\u672c\u81e8\u5e8a\u7d30\u80de\u5b66\u4f1a\u4e5d\u5dde\u9023\u5408\u4f1a\u96d1\u8a8c. 2005;36:23-28. (7\u6708)<\/li>\n
      4. \u5c71\u672c\u5fb9, \u68b6\u7530\u82b3\u5f18, \u9ad8\u5c4b\u548c\u5fd7, \u6885\u6728\u4e00\u7f8e, \u5c0f\u8c37\u5bcc\u7537, \u5ca1\u5c71\u662d\u5f66. \u7532\u72b6\u817a\u30da\u30eb\u30aa\u30ad\u30b7\u30c0\u30fc\u30bc\u907a\u4f1d\u5b50\u306e\u95a2\u4e0e\u3092\u8a8d\u3081\u305f\u5148\u5929\u6027\u7532\u72b6\u817a\u6a5f\u80fd\u4f4e\u4e0b\u75c7\u306e\u540c\u80de\u4f8b. \u30db\u30eb\u30e2\u30f3\u3068\u81e8\u5e8a\u30002006;54:96-100. (2\u6708)<\/li>\n
      5. \u5bae\u5185\u4fca\u4e00, \u84ee\u6c60\u609f, \u9ed2\u6728\u7a63\u4e8c, \u5742\u5143\u79c0\u675c, \u6c38\u7530\u8ce2\u6cbb, \u5b87\u90fd\u6d69\u6587, \u6797\u514b\u88d5, \u5357\u5bdb\u4e4b,\u576a\u5185\u535a\u4ec1. \u6297\u6838\u6297\u4f53\u9670\u6027\u3001\u809d\u814e\u30de\u30a4\u30af\u30ed\u30be\u30fc\u30e0-1\u6297\u4f53\u9670\u6027\u3067\u3001\u6297\u5e73\u6ed1\u7b4b\u6297\u4f53\u9670\u6027\u3067\u3042\u3063\u305f\u81ea\u5df1\u514d\u75ab\u6027\u809d\u708e\u306e1\u4f8b. \u5bae\u5d0e\u770c\u533b\u5e2b\u4f1a\u533b\u5b66\u4f1a\u8a8c\u30002006;30:1,45-49. (3\u6708)<\/li>\n<\/ol>\n

        \u3010\u7dcf\u8aac\u3011<\/h4>\n
          \n
        1. \u5ca1\u5c71\u662d\u5f66. \u30ec\u30b8\u30aa\u30cd\u30e9\u75c7\uff1a\u56fd\u5185\u306b\u304a\u3051\u308b\u30a2\u30a6\u30c8\u30d6\u30ec\u30a4\u30af\uff0e\u81e8\u5e8a\u3068\u5fae\u751f\u7269.\u30002005;32: 360-364. (7\u6708)<\/li>\n
        2. \u5ca1\u5c71\u662d\u5f66. HTLV-1\u611f\u67d3\u306e\u81ea\u7136\u53f2. \u81e8\u5e8a\u75c5\u7406. 2005;53:837-844. (9\u6708)<\/li>\n
        3. \u9577\u53cb\u5b89\u5f18. \u81e8\u5e8a\u306b\u5f79\u7acb\u3064\u547c\u5438\u5668\u75c5\u5b66(3)\u3000\u9589\u585e\u6027\u80ba\u75be\u60a3\uff0d\u6c17\u7ba1\u652f\u5598\u606f\u3000COPD\u3092\u4e2d\u5fc3\u3068\u3057\u3066\uff0d. \u5bae\u5d0e\u770c\u5185\u79d1\u533b\u4f1a\u8a8c.\u30002005;68:40-48. (10\u6708)<\/li>\n
        4. \u6885\u6728\u4e00\u7f8e. \u7532\u72b6\u817a\u30da\u30eb\u30aa\u30ad\u30b7\u30c0\u30fc\u30bc\u306e\u5206\u5b50\u7570\u5e38. \u81e8\u5e8a\u5206\u5b50\u5185\u5206\u6ccc\u5b663 -\u7532\u72b6\u817a\u30fb\u526f\u7532\u72b6\u817a\u30fb\u9aa8\u5185\u5206\u6ccc\u4ee3\u8b1d\u7cfb-. \u65e5\u672c\u81e8\u5e8a.\u30002005;880:24-30\u3000\u5897\u520a\u53f7. (10\u6708)<\/li>\n
        5. \u9577\u53cb\u5b89\u5f18.\u3000\u81e8\u5e8a\u306b\u5f79\u7acb\u3064\u547c\u5438\u5668\u75c5\u5b66(4)\u3000\u9593\u8cea\u6027\u80ba\u75be\u60a3.\u3000\u5bae\u5d0e\u770c\u5185\u79d1\u533b\u4f1a\u8a8c. 2006;69:37-46. (3\u6708)<\/li>\n<\/ol>\n
          \"\u3053\u306e\u30da\u30fc\u30b8\u306e\u5148\u982d\u3078\"<\/a><\/div>\n

          B. \u767a\u8868<\/h3>\n

          \u3010\u5b66\u4f1a\u767a\u8868\u3011<\/h4>\n
            \n
          1. \u7530\u4e2d\u5f26\u4e00, \u5ca1\u5c71\u662d\u5f66, \u6885\u5317\u90a6\u5f66, \u9db4\u6751\u4f73\u4eba\u5b50, \u4e0a\u91ce\u53f2\u90ce, \u9ad8\u57ce\u4e00\u90ce, \u7532\u6590\u6cf0\u6587,\u68ee\u7950\u4e00\u90ce, \u9ed2\u6728\u660c\u5e78, \u4f50\u3005\u6728\u9686, \u576a\u5185\u535a\u4ec1, \u4e45\u7530\u5145\u7d75. \u914d\u5076\u8005\u9593\u304a\u3088\u3073\u6bcd\u5150\u9593\u611f\u67d3HTLV-1\u6297\u4f53\u967d\u8ee2\u8005\u306e\u611f\u67d3\u7d30\u80de\u30af\u30ed\u30fc\u30ca\u30ea\u30c6\u30a3\u306e\u691c\u8a0e. \u7b2c79\u56de\u65e5\u672c\u611f\u67d3\u75c7\u5b66\u4f1a\u7dcf\u4f1a. 2005. (4\u6708, \u611b\u77e5\u770c\u540d\u53e4\u5c4b\u5e02)<\/li>\n
          2. \u767d\u571f\u660e\u7f8e, \u9ad8\u57ce\u4e00\u90ce, \u9db4\u6751\u4f73\u4eba\u5b50, \u4e0a\u91ce\u53f2\u90ce, \u7532\u6590\u6cf0\u6587, \u7530\u4e2d\u5f26\u4e00, \u9ed2\u6728\u660c\u5e78,\u4f50\u3005\u6728\u9686, \u5ca1\u5c71\u662d\u5f66, \u576a\u5185\u535a\u4ec1. \u5927\u8178\u61a9\u5ba4\u708e\u304c\u539f\u56e0\u3068\u8003\u3048\u3089\u308c\u305f prevotella loesheii \u6557\u8840\u75c7\u306b\u4f34\u3046\u4e0a\u8178\u9593\u819c\u9759\u8108\u8840\u6813\u75c7\u306e\u4e00\u4f8b. \u7b2c79\u56de\u65e5\u672c\u611f\u67d3\u75c7\u5b66\u4f1a\u7dcf\u4f1a. 2005. (4\u6708, \u611b\u77e5\u770c\u540d\u53e4\u5c4b\u5e02)<\/li>\n
          3. \u9db4\u6751\u4f73\u4eba\u5b50, \u6885\u5317\u90a6\u5f66, \u4e0a\u91ce\u53f2\u90ce, \u9ad8\u57ce\u4e00\u90ce, \u7532\u6590\u6cf0\u6587, \u7530\u4e2d\u5f26\u4e00, \u9ed2\u6728\u660c\u5e78,\u4f50\u3005\u6728\u9686, \u5ca1\u5c71\u662d\u5f66, \u576a\u5185\u535a\u4ec1. \u5f53\u79d1\u306b\u304a\u3051\u308b\u9593\u8cea\u80ba\u708e\u3092\u5408\u4f75\u3057\u305f\u76ae\u819a\u708e\u306e\u691c\u8a0e.\u7b2c49\u56de\u65e5\u672c\u30ea\u30a6\u30de\u30c1\u5b66\u4f1a\u7dcf\u4f1a\u30fb\u5b66\u8853\u96c6\u4f1a. 2005. (4\u6708, \u795e\u5948\u5ddd\u770c\u6a2a\u6d5c\u5e02)<\/li>\n
          4. \u9ed2\u6728\u660c\u5e78, \u6885\u5317\u90a6\u5f66, \u9db4\u6751\u4f73\u4eba\u5b50, \u9ad8\u57ce\u4e00\u90ce, \u7532\u6590\u6cf0\u6587, \u7530\u4e2d\u5f26\u4e00, \u4f50\u3005\u6728\u9686,\u5ca1\u5c71\u662d\u5f66, \u576a\u5185\u535a\u4ec1. \u5168\u8eab\u6027\u30a8\u30ea\u30c6\u30de\u30c8\u30fc\u30c7\u30b9(SLE)\u5408\u4f75\u598a\u5a20\u30fb\u51fa\u7523\u306e\u81e8\u5e8a\u7684\u691c\u8a0e. \u7b2c49\u56de\u65e5\u672c\u30ea\u30a6\u30de\u30c1\u5b66\u4f1a\u7dcf\u4f1a\u30fb\u5b66\u8853\u96c6\u4f1a. 2005. (4\u6708, \u795e\u5948\u5ddd\u770c\u6a2a\u6d5c\u5e02)<\/li>\n
          5. \u4e0a\u91ce\u53f2\u90ce, \u4f50\u3005\u6728\u9686, \u6885\u5317\u90a6\u5f66, \u9db4\u6751\u4f73\u4eba\u5b50, \u9ad8\u57ce\u4e00\u90ce, \u7532\u6590\u6cf0\u6587, \u9ed2\u6728\u660c\u5e78,\u576a\u5185\u535a\u4ec1, \u7530\u4e2d\u5f26\u4e00, \u5ca1\u5c71\u662d\u5f66. \u76ae\u819a\u7b4b\u708e\u306b\u5408\u4f75\u3057\u305f\u9593\u8cea\u6027\u80ba\u708e\u306e\u81e8\u5e8a\u7684\u691c\u8a0e. \u7b2c45\u56de\u65e5\u672c\u547c\u5438\u5668\u5b66\u4f1a\u7dcf\u4f1a. 2005. (4\u6708, \u5343\u8449\u770c)<\/li>\n
          6. \u8352\u6b66\u516b\u8d77, \u6e05\u5c71\u548c\u662d, \u4f50\u85e4\u4fe1\u4e5f, \u5927\u91ce\u62db\u4f38, \u65e5\u91ce\u6d66\u96c4\u4e4b, \u6817\u6797\u5fe0\u4fe1, \u4e38\u585a\u6d69\u52a9,\u5ca1\u5c71\u662d\u5f66, \u7530\u6751\u548c\u592b. \u7532\u72b6\u817a\u4e73\u982d\u764c\u306e\u5206\u5316\u5ea6\u63a8\u5b9a\u306b\u304a\u3051\u308bDPPIV\u6d3b\u6027\u67d3\u8272\u306e\u6709\u7528\u6027. \u7b2c46\u56de\u65e5\u672c\u81e8\u5e8a\u7d30\u80de\u5b66\u4f1a\u7dcf\u4f1a. 2005. (5\u6708, \u798f\u5ca1\u770c)<\/li>\n
          7. Shoda M, Ito M, Aizawa S, Ishida T, Aoki S, Maruyama-Nagai M, Kuroki R, Utsunomiya A, Koga S, Okayama A, Yamada Y, Kamihira S, Uozumi K, Kikuchi H, Yamaguchi K, Watanabe S, Watanabe T. Characterization of the expression profile signature of ATL cells and detection of ATL cells in vivo. 12th International conference on human retrovirology. 2005. (June, Jamaica)<\/li>\n
          8. Mueller NE, Okayama A, Stuver SO, Cranston B, Hanchard B, Birmann B, Hisada M. The epidemiology of HTLV-1 infection: Where do we go from here 12th International conference on human retrovirology. 2005. (June, Jamaica)<\/li>\n
          9. Birmann B, Mueller NE, Breen EC, Stuver SO, Okayama A, MartINez-Maza O, Raker CA, Aziz N, Li H, Cranston B, Hanchard B, Hisada M. HTLV-1 infection is associated with elevated plasma biomarkers of immune activation in Jamaican but not in Japanease carriers. 12th International conference on human retrovirology. 2005. (June, Jamaica)<\/li>\n
          10. \u5c71\u672c\u5fb9, \u68b6\u7530\u82b3\u5f18, \u6885\u6728\u4e00\u7f8e, \u5ca1\u5c71\u662d\u5f66. \u7532\u72b6\u817a\u30da\u30eb\u30aa\u30ad\u30b7\u30c0\u30fc\u30bc\u907a\u4f1d\u5b50\u5909\u7570\u306e\u95a2\u4e0e\u3092\u307f\u3068\u3081\u305f\u5148\u5929\u6027\u7532\u72b6\u817a\u6a5f\u80fd\u4f4e\u4e0b\u75c7\u306e\u540c\u80de\u4f8b. \u7b2c78\u56de\u65e5\u672c\u5185\u5206\u6ccc\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a. 2005. (7\u6708, \u6771\u4eac\u90fd)<\/li>\n
          11. \u6e21\u9089\u4fca\u6a39, \u6b63\u7530\u6843\u5b50, \u76f8\u6fa4\u7e41\u7f8e, \u77f3\u7530\u5c1a\u81e3, \u4e0a\u5e73\u61b2, \u5b87\u90fd\u5bae\u8208, \u9b5a\u4f4f\u516c\u6cbb, \u5ca1\u5c71\u662d\u5f66, \u83ca\u6c60\u535a, \u53e4\u8cc0\u9707, \u7530\u53e3\u535a\u56fd, \u4e38\u5185\u85ab, \u5c71\u53e3\u4e00\u6210. \u5408\u6210DNA\u30a2\u30ec\u30a4\u89e3\u6790\u306b\u3088\u308b\u907a\u4f1d\u5b50\u767a\u73fe\u30b7\u30b0\u30cb\u30c1\u30e3\u30fc\u3092\u7528\u3044\u305fATL\u7d30\u80de\u306e\u9ad8\u611f\u5ea6\u691c\u51fa\u7cfb\u306e\u78ba\u7acb. \u7b2c67\u56de\u65e5\u672c\u8840\u6db2\u5b66\u4f1a\u30fb\u7b2c47\u56de\u65e5\u672c\u81e8\u5e8a\u8840\u6db2\u5b66\u4f1a\u7dcf\u4f1a. 2005. (8\u6708, \u795e\u5948\u5ddd\u770c\u6a2a\u6d5c\u5e02)<\/li>\n
          12. \u5ca1\u5c71\u662d\u5f66, \u7530\u4e2d\u5f26\u4e00, \u91ce\u6751\u5275. \u7570\u306a\u308b\u611f\u67d3\u7d4c\u8def\u306b\u3088\u308bHTLV-1\u611f\u67d3\u7d30\u80de\u30af\u30ed\u30fc\u30ca\u30ea\u30c6\u30a3\u306e\u6210\u7acb\u904e\u7a0b\u306e\u691c\u8a0e. \u7b2c64\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a. 2005. (9\u6708, \u5317\u6d77\u9053\u672d\u5e4c\u5e02)<\/li>\n
          13. \u5bae\u5185\u4fca\u4e00, \u9db4\u6751\u4f73\u4eba\u5b50, \u6885\u5317\u90a6\u5f66, \u9ed2\u6728\u660c\u5e78, \u4f50\u3005\u6728\u9686, \u7532\u6590\u6cf0\u6587, \u9ad8\u57ce\u4e00\u90ce,\u7530\u4e2d\u5f26\u4e00, \u5ca1\u5c71\u662d\u5f66. \u591a\u5f69\u306a\u514d\u75ab\u7570\u5e38\u3092\u793a\u3057\u305f\u597d\u9178\u7403\u6027\u7b4b\u819c\u708e\u306e\u4e00\u4f8b. \u7b2c30\u56de\u4e5d\u5dde\u30ea\u30a6\u30de\u30c1\u5b66\u4f1a. 2005. (9\u6708, \u9e7f\u5150\u5cf6\u770c)<\/li>\n
          14. \u77f3\u9ed2\u9686\u4e00, \u7dd2\u65b9\u826f\u4e00, \u5927\u5ca9\u6839\u4e9c\u5e0c, \u5b88\u7530\u6b63\u5ba3, \u6728\u7530\u4fe1\u7ae0, \u7dd2\u65b9\u967d\u4e00. \u8fc5\u901f\u30fb\u30c0\u30a6\u30f3\u5bfe\u7b56\u5bfe\u5fdc\u751f\u5316\u5b66\u691c\u67fb\u30b7\u30b9\u30c6\u30e0\u306e\u69cb\u7bc9. \u7b2c40\u56de\u4e5d\u5dde\u533b\u5b66\u691c\u67fb\u5b66\u4f1a.\u30002005. (10\u6708, \u798f\u5ca1\u770c)<\/li>\n
          15. \u8352\u6b66\u516b\u8d77. CD26 \/ DPPIV\u306e\u81e8\u5e8a\u7d30\u80de\u5b66\u304a\u3088\u3073\u7d44\u7e54\u5b66\u3078\u306e\u5fdc\u7528\u3068\u8a3a\u65ad\u7684\u4fa1\u5024\u306e\u691c\u8a3c -14\u5e74\u9593\u306b\u308f\u305f\u308b\u95a2\u9023\u75c5\u9662\u3068\u306e\u5171\u540c\u7814\u7a76\u304b\u3089-. \u7b2c44\u56de\u5bae\u5d0e\u770c\u533b\u5b66\u691c\u67fb\u5b66\u4f1a\u30002005. (11\u6708, \u5bae\u5d0e\u770c)<\/li>\n
          16. \u8352\u6b66\u516b\u8d77, \u6885\u6728\u4e00\u7f8e, \u5c71\u672c\u6210\u90ce, \u7af9\u30ce\u5185\u535a\u4e4b, \u91ce\u6751\u5275, \u7530\u6751\u548c\u592b, \u5ca1\u5c71\u662d\u5f66. \u30d2\u30c8\u7532\u72b6\u817a\u672a\u5206\u5316\u764c\u7d30\u80de\u682aTTA-1\u306b\u304a\u3051\u308bCD26\/DPPIV\u306e\u5f79\u5272. \u7b2c52\u56de\u65e5\u672c\u81e8\u5e8a\u691c\u67fb\u533b\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a.\u30002005. (11\u6708, \u798f\u5ca1\u770c)<\/li>\n
          17. \u6885\u6728\u4e00\u7f8e, \u7530\u4e2d\u5f26\u4e00, \u91ce\u6751\u5275, \u5ca1\u5c71\u662d\u5f66. HTLV-1\u611f\u67d3\u30ad\u30e3\u30ea\u30a2\u304a\u3088\u3073\u914d\u5076\u8005\u9593\u611f\u67d3\u8005\u306b\u304a\u3051\u308b\u611f\u67d3\u7d30\u80de\u30af\u30ed\u30fc\u30f3\u306e\u5897\u6b96\u3068\u7d44\u307f\u8fbc\u307f\u90e8\u4f4d\u306e\u89e3\u6790: \u7b2c52\u56de\u65e5\u672c\u81e8\u5e8a\u691c\u67fb\u533b\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a.\u30002005. (11\u6708, \u798f\u5ca1\u770c)<\/li>\n
          18. \u4e0a\u91ce\u53f2\u90ce, \u5bae\u5185\u4fca\u4e00, \u6885\u5317\u90a6\u5f66, \u9ed2\u6728\u660c\u5e78, \u4f50\u3005\u6728\u9686, \u7532\u6590\u6cf0\u6587, \u9ad8\u57ce\u4e00\u90ce, \u5ca1\u5c71\u662d\u5f66. \u9ad8\u03b3\u30b0\u30ed\u30d6\u30ea\u30f3\u8840\u75c7\u306b\u3088\u308b\u7d2b\u6591\u75c5\u306e\u52a0\u7642\u4e2d\u306b\u5168\u8eab\u578b\u975e\u5b9a\u578b\u578b\u6297\u9178\u83cc\u75c7\u3092\u767a\u75c7\u3057\u305f\uff11\u4f8b. \u7b2c75\u56de\u65e5\u672c\u611f\u67d3\u75c7\u5b66\u4f1a\u897f\u65e5\u672c\u5730\u65b9\u4f1a\u7dcf\u4f1a. 2005. (11\u6708, \u9577\u5d0e\u770c)<\/li>\n
          19. \u6b66\u77e5\u9032\u58eb, \u4f0a\u85e4\u8302, \u6b66\u7530\u653b, \u91ce\u6751\u5275, \u5cf0\u677e\u4fca\u592b, \u5c71\u53e3\u5fe0\u654f. \u7cd6\u7531\u6765\u306e\u5909\u5316\u751f\u6210\u7269dihydropyrazine\uff08DHP\uff09\u985e\u306b\u3088\u308b\u6d3b\u6027\u9178\u7d20\u30b9\u30c8\u30ec\u30b9. \u7b2c28\u56de\u65e5\u672c\u5206\u5b50\u751f\u7269\u5b66\u4f1a\u5e74\u4f1a.\u30002005. (12\u6708, \u798f\u5ca1\u770c)<\/li>\n
          20. \u91ce\u6751\u5275, \u4f0a\u85e4\u8302, \u6b66\u77e5\u9032\u58eb, \u5cf0\u677e\u4fca\u592b, \u5ca1\u5c71\u662d\u5f66, \u5c71\u53e3\u5fe0\u654f. \u7cd6\u7531\u6765dihydropyrazine\uff08DHP\uff09\u985e\u306ephenyl\u8a98\u5c0e\u4f53\u306e\u7d30\u80de\u6a5f\u80fd\u3078\u306e\u5f71\u97ff: \u7b2c28\u56de\u65e5\u672c\u5206\u5b50\u751f\u7269\u5b66\u4f1a\u5e74\u4f1a.\u30002005. (12\u6708, \u798f\u5ca1\u770c)<\/li>\n
          21. \u5bae\u5185\u4fca\u4e00, \u6885\u5317\u90a6\u5f66, \u4e0a\u91ce\u53f2\u6717, \u9ed2\u6728\u660c\u5e78, \u4f50\u3005\u6728\u9686, \u7532\u6590\u6cf0\u6587, \u9ad8\u57ce\u4e00\u90ce, \u5ca1\u5c71\u662d\u5f66. \u591a\u767a\u6027\u7b4b\u708e\u306e\u52a0\u7642\u4e2d\u306b\u64ad\u7a2e\u6027\u975e\u7d50\u6838\u6027\u6297\u9178\u83cc\u75c7\u3092\u767a\u75c7\u3057\u305f\u4e00\u4f8b.\u3000\u7b2c272\u56de\u65e5\u672c\u5185\u79d1\u5b66\u4f1a\u4e5d\u5dde\u5730\u65b9\u4f1a.\u30002006. (1\u6708, \u798f\u5ca1\u770c)<\/li>\n
          22. \u798f\u7530\u771f\u5f13, \u6b66\u7530\u5343\u7a42, \u524d\u7530\u3072\u3068\u307f, \u5ca1\u5c71\u662d\u5f66. \u5bae\u5d0e\u5927\u5b66\u9644\u5c5e\u75c5\u9662\u306b\u304a\u3051\u308b\u91dd\u523a\u3057\u30fb\u5207\u5275\u306b\u3088\u308b\u8840\u6db2\u66b4\u9732\u4e8b\u6545\u9632\u6b62\u4ecb\u5165\u306b\u3064\u3044\u3066\u306e\u691c\u8a0e.\u3000\u7b2c21\u56de\u65e5\u672c\u74b0\u5883\u611f\u67d3\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a. 2006. (2\u6708, \u6771\u4eac\u90fd)<\/li>\n
          23. \u5bae\u5185\u4fca\u4e00, \u6885\u5317\u90a6\u5f66, \u4e0a\u91ce\u53f2\u6717, \u6960\u672c\u61b2\u751f, \u9db4\u6751\u4f73\u4eba\u5b50, \u9ad8\u57ce\u4e00\u90ce, \u7532\u6590\u6cf0\u6587,\u9ed2\u6728\u660c\u5e78, \u4f50\u3005\u6728\u9686, \u5ca1\u5c71\u662d\u5f66. \u65e9\u671f\u8a3a\u65ad\u3068\u75be\u60a3\u6d3b\u52d5\u6027\u306e\u8a55\u4fa1\u306b[18F]FDG-PET\u304c\u6709\u52b9\u3067\u3042\u3063\u305f\u9ad8\u5b89\u52d5\u8108\u708e\u306e1\u4f8b.\u3000\u7b2c31\u56de\u4e5d\u5dde\u30ea\u30a6\u30de\u30c1\u5b66\u4f1a. 2006. (3\u6708, \u5bae\u5d0e\u770c)<\/li>\n
          24. \u5927\u5e73\u6d0b\u660e, \u5bae\u5185\u4fca\u4e00, \u6885\u5317\u90a6\u5f66, \u4e0a\u91ce\u53f2\u6717, \u9ed2\u6728\u660c\u5e78, \u4f50\u3005\u6728\u9686, \u7532\u6590\u6cf0\u6587, \u9ad8\u57ce\u4e00\u90ce, \u5ca1\u5c71\u662d\u5f66, \u53e4\u8cc0\u6cbb\u5e78, \u69ae\u5efa\u6587, \u524d\u7530\u5b8f\u4e00. \u6df1\u90e8\u9759\u8108\u8840\u6813\u75c7\u3068\u591a\u767a\u6027\u80ba\u6897\u585e\u3092\u304d\u305f\u3057\u305f\u6297\u30ea\u30f3\u8102\u8cea\u6297\u4f53\u75c7\u5019\u7fa4\uff08APS\uff09\u306e\u4e00\u4f8b.\u3000\u7b2c31\u56de\u4e5d\u5dde\u30ea\u30a6\u30de\u30c1\u5b66\u4f1a. 2006. (3\u6708, \u5bae\u5d0e\u770c)<\/li>\n
          25. \u8352\u6b66\u516b\u8d77, \u65e5\u91ce\u6d66\u96c4\u4e4b, \u4f50\u85e4\u4fe1\u4e5f, \u5927\u91ce\u62db\u4f38, \u4e38\u585a\u6d69\u52a9, \u5c71\u53e3\u79c0\u6a39, \u5ca1\u5c71\u662d\u5f66. \u6162\u6027\u7532\u72b6\u817a\u708e\u69d8\u306e\u7d30\u80de\u50cf\u304b\u3089\u60aa\u6027\u30ea\u30f3\u30d1\u816b\u69d8\u7d30\u80de\u50cf\u3078\u306e\u79fb\u884c\u304c\u8ffd\u3048\u305f\u75c7\u4f8b\u306e\u691c\u8a0e. \u7b2c22\u56de\u65e5\u672c\u81e8\u5e8a\u7d30\u80de\u5b66\u4f1a\u5bae\u5d0e\u652f\u90e8\u7dcf\u4f1a. 2006. (3\u6708, \u5bae\u5d0e\u770c)<\/li>\n
          26. \u6b66\u77e5\u9032\u58eb, \u4f0a\u85e4 \u8302, \u6b66\u7530\u653b, \u91ce\u6751\u5275, \u5cf0\u677e\u4fca\u592b, \u5c71\u53e3\u5fe0\u654f. \u7cd6\u7531\u6765\u306e\u5909\u5316\u751f\u6210\u7269: dihydropyrazine\u985e\u306b\u3088\u308b\u9178\u5316\u30b9\u30c8\u30ec\u30b9. \u65e5\u672c\u85ac\u5b66\u4f1a\u3000\u7b2c126\u5e74\u4f1a.\u30002006. (3\u6708,\u5bae\u57ce\u770c\u4ed9\u53f0\u5e02)<\/li>\n<\/ol>\n
            \"\u3053\u306e\u30da\u30fc\u30b8\u306e\u5148\u982d\u3078\"<\/a><\/div>\n

            C. \u305d\u306e\u4ed6<\/h3>\n
              \n
            1. \u6885\u6728\u4e00\u7f8e. \u5148\u5929\u6027\u7532\u72b6\u817a\u6a5f\u80fd\u4f4e\u4e0b\u75c7\u306e\u907a\u4f1d\u5b50\u691c\u67fb. \u5bae\u5d0e\u5927\u5b66\u533b\u5b66\u90e8\u907a\u4f1d\u30ab\u30a6\u30f3\u30bb\u30ea\u30f3\u30b0\u90e8\u7b2c3\u56de\u30ab\u30f3\u30d5\u30a1\u30ec\u30f3\u30b9. 2005. (4\u6708, \u5bae\u5d0e\u5927\u5b66\u533b\u5b66\u90e8)<\/li>\n
            2. \u6885\u6728\u4e00\u7f8e.\u3000\u5b66\u4f1a\u5370\u8c61\u8a18-\u7b2c52\u56de\u65e5\u672c\u81e8\u5e8a\u691c\u67fb\u533b\u5b66\u4f1a\u3000\u691c\u67fb\u3068\u6280\u8853.\u30002006;34:168. (2\u6708)<\/li>\n<\/ol>\n
              \"\u3053\u306e\u30da\u30fc\u30b8\u306e\u5148\u982d\u3078\"<\/a><\/div>\n

              D. \u7279\u8a31\u51fa\u9858<\/h3>\n
                \n
              1. \u5ca1\u5c71\u662d\u5f66. \u51fa\u9858\u756a\u53f7\u3000\u7279\u9858\uff12\uff10\uff10\uff16\uff0d\uff19\uff11\uff12\uff18\uff16\u3000\u51fa\u9858\u65e5\u30002006\/03\/29\u767a\u660e\u306e\u540d\u79f0\u3000\u6210\u4ebaT\u7d30\u80de\u767d\u8840\u75c5\u30de\u30fc\u30ab\u30fc.<\/li>\n<\/ol>\n
                \"\u3053\u306e\u30da\u30fc\u30b8\u306e\u5148\u982d\u3078\"<\/a><\/div>\n

                <\/p>\n

                \u5185\u8a33\u6570<\/h2>\n

                A.\u8ad6\u6587\uff1a\u8457\u66f8(1)\u3001\u539f\u8457\uff087\uff09\u3001\u75c7\u4f8b\u5831\u544a\uff08\u8ad6\u6587\uff09\uff085\uff09\u3001\u7dcf\u8aac\uff085\uff09\u3000B.\u767a\u8868\uff1a\u5b66\u4f1a\u767a\u8868\uff0826\uff09\u3001\u305d\u306e\u4ed6\uff080\uff09 C.\u305d\u306e\u4ed6\uff082\uff09\u3000D.\u7279\u8a31\u51fa\u9858\uff081\uff09<\/p>\n","protected":false},"excerpt":{"rendered":"

                A. \u8ad6\u6587 \u3010\u8457\u66f8\u3011 \u5ca1\u5c71\u662d\u5f66. \u611f\u67d3\u75c7\u304a\u3088\u3073\u5bc4\u751f\u866b\u75be\u60a3. \u533b\u7642\u7981\u5fcc\u8a3a\u7642\u79d1\u5225\u30de\u30cb\u30e5\u30a2\u30eb, \u5bcc\u91ce\u5eb7\u65e5\u5df1, 224-241(2006).\u3000\u533b\u6b6f\u85ac\u51fa\u7248\u682a\u5f0f\u4f1a\u793e, \u6771\u4eac. (3\u6708) \u3010\u539f\u8457\u3011 Tanaka G, Okayama […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_mi_skip_tracking":false},"categories":[9],"tags":[],"_links":{"self":[{"href":"http:\/\/www.med.miyazaki-u.ac.jp\/home\/menekikansen\/wp-json\/wp\/v2\/posts\/224"}],"collection":[{"href":"http:\/\/www.med.miyazaki-u.ac.jp\/home\/menekikansen\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.med.miyazaki-u.ac.jp\/home\/menekikansen\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.med.miyazaki-u.ac.jp\/home\/menekikansen\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/www.med.miyazaki-u.ac.jp\/home\/menekikansen\/wp-json\/wp\/v2\/comments?post=224"}],"version-history":[{"count":0,"href":"http:\/\/www.med.miyazaki-u.ac.jp\/home\/menekikansen\/wp-json\/wp\/v2\/posts\/224\/revisions"}],"wp:attachment":[{"href":"http:\/\/www.med.miyazaki-u.ac.jp\/home\/menekikansen\/wp-json\/wp\/v2\/media?parent=224"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.med.miyazaki-u.ac.jp\/home\/menekikansen\/wp-json\/wp\/v2\/categories?post=224"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.med.miyazaki-u.ac.jp\/home\/menekikansen\/wp-json\/wp\/v2\/tags?post=224"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}